Print this pageBEST-BTK: 12-Month Data Of the Use Of the Biotronik Absorbable Metal Stent Below the Knee
Back to 33rd Annual Symposium
Back to Final Program
Abstract 16
Marc Bosiers, MD1, Patrick Peeters, MD2, Koen Deloose, MD1, Jürgen Verbist, MD2.
1AZ St-Blasius, Dendermonde, Belgium, 2Imelda Hospital, Bonheiden, Belgium.
Background:
The study was designed to evaluate the safety and performance of a new metal absorbable metal stent for the treatment of infrapopliteal occlusive disease. The use of absorbable material during stenting removes the trigger for neo-intima hyperplasia and therefore potentially lowers in-stent restenosis.
Methods:
From December 2003 to January 2004, 20 patients with chronic CLI caused by infrapopliteal occlusive disease were prospectively identified and included in a Phase I clinical trial. Patients were followed for adverse events with comprehensive laboratory analysis and clinical exam. Surveillance of stent performance was investigated by CFDU and MRA. 6-month limb salvage defined the primary endpoint.
Results:
All stents are deployed successfully as confirmed by intra-operative angiography and IVUS. The alloy shows to be MRA-compatible, allowing MRA for vessel control. The 1-month CFDU and MRA confirm the start of the stent absorption process. Six months after implantation limb salvage is achieved in 94.7% of the patients and CFDU shows a primary patency rate of 78.9%. Serum and blood analysis reveals no systemic toxicity from the implanted metal alloy. 12-month data regarding mid-term limb salvage and vessel patency will be available at the time of the meeting.
Conclusion:
This study is the first to report the implantation of a metal bio-absorbable stents in man for the treatment of arterial occlusive disease. Immediate results show good bio- and MRA-compatibility of the absorbable metal stents, while 6-month data confirm the excellent expected limb salvage. 